Abstract:Introduction: Liver transplantation (LT) is a life-saving procedure that resolves complications of cirrhosis. However, the metabolic risk factors for nonalcoholic fatty liver disease (NAFLD) persist and potentially worsen in the post-transplant setting, thereby increasing the risk of liver fibrosis. Liver biopsy is the gold standard to diagnose NAFLD and liver fibrosis, but this procedure is invasive and less than ideal for longitudinal monitoring after LT. We aimed to investigate the association of serum steatosis and fibrosis biomarkers with mortality and graft loss in LT recipients. Methods: We included consecutive adults who received a liver transplant at the MUHC in 2014-2021 and were followed up annually. The outcomes measured were death and graft loss, graft loss being defined as graft failure leading to death or re-transplantation. We assessed the prognostic value of the biomarkers ALT, AST, GGT, AST-to-Platelet Ratio Index (APRI), fibrosis-4 index (FIB-4), and hepatic steatosis index (HSI). Hepatic steatosis was defined as HSI >36, and liver fibrosis was characterized as FIB-4 > 3.64 or APRI > 1. Survival analysis and Generalized Estimating Equation (GEE) models were used to assess the association between the biomarkers and the outcomes. Results: Two hundred nineteen patients were followed for 30 months on average. Graft loss and mortality occurred in 12 patients (9%) and 38 (29.5%) resulting in incidence rates of 29.5 (95% CI 20.9-40.6) and 9.6 (95% CI 5-16.8) per 100 person-years, respectively. Patients who died during the follow-up were older, had an older donor, and had a history of diabetes. On multivariable analysis using the GEE model (see Table 1), higher ALT and higher AST were associated with mortality after adjustment for sex, BMI, age, albumin, and platelets. In the time-to-event analysis, the Kaplan Meier curves showed that APRI >1 could be a potential predictor of mortality (P = 0.0729 see Figure 1). Neither FIB-4 (log-rank, P = 0.199) nor HSI (log-rank, P = 0.919) were associated with mortality. None of the biomarkers or liver transaminases were associated with graft loss. Conclusion: Liver transaminases and the serum fibrosis biomarker APRI are associated with mortality in LT recipients. The hepatic steatosis biomarker HSI does not seem to be valuable in predicting outcomes in this population. None among liver transaminases, steatosis or fibrosis biomarkers predicted graft loss. Table 1. - GEE of liver transaminases on death in LT patients Characteristics Univariate Multi-Variate * Odds Ratio 95% CI P-value Odds Ratio 95% CI P-value ALT Moderate/Severe 0.9999 0.9999–1.0000 0.0931 1.0001 1.0000–1.0002 0.0040 AST Moderate/Severe 1.0000 0.9999–1.0000 0.3934 1.0001 1.0000–1.0001 0.0037 ALP Moderate/Severe 0.9999 0.9996–1.0001 0.2807 1.0000 0.9998–1.0001 0.6113 GGT Moderate/Severe 0.9998 0.9996–1.0000 0.0236 0.9998 0.9997–1.0000 0.0596 Smoking status No 1.00 1.00 Yes 0.921 0.71–1.20 0.5444 0.934 0.74–1.18 0.5649 *multivariate models are adjusted for age, sex, albumin, BMI and platelets. Figure 1.: Kaplan-Meier survival curve in LT patients according to the APRI biomarker.

The Predictive Value of Graft Viability and Bioenergetics Testing Towards the Outcome in Liver Transplantation

Mitochondrial respiration during normothermic liver machine perfusion predicts clinical outcome

Predictive value of early postoperative lactate (<6 h) during normothermic machine perfusion and outcome after liver transplantation: results from a multicentre study

Viability Assessment in Liver Transplantation—What Is the Impact of Dynamic Organ Preservation?

Bioenergetic and Cytokine Profiling May Help to Rescue More DCD Livers for Transplantation

Liver function maximum capacity test during normothermic regional perfusion predicts graft function after transplantation

Cell-specific Extracellular Vesicles and Their miRNA Cargo Released Into the Organ Preservation Solution During Cold Ischemia Storage as Biomarkers for Liver Transplant Outcomes

Serum Fibrosis and Steatosis Biomarkers for the Prediction of Mortality in Liver Transplant Recipients

Clinical outcomes prediction in kidney transplantation by use of biomarkers from hypothermic machine perfusion

Assessment of liver graft quality during hypothermic oxygenated perfusion: the first international validation study

The BAR Score Predicts and Stratifies Outcomes Following Liver Retransplantation: Insights From a Retrospective Cohort Study

Protein Profiles of Pretransplant Grafts Predict Early Allograft Dysfunction After Liver Transplantation From Donation After Circulatory Death.

Development of a Novel Prognostic Nomogram for High Model for End-Stage Liver Disease Score Recipients Following Deceased Donor Liver Transplantation

Advancements in Predictive Tools for Primary Graft Dysfunction in Liver Transplantation: A Comprehensive Review

Optimization of surgical evaluation algorithms for living donor liver transplantation

Transcriptomic signatures during normothermic liver machine perfusion correspond with graft quality and predict the early graft function

A randomized trial of normothermic preservation in liver transplantation

Lactate concentration at the end of liver transplant: Early predictor of graft function or just one piece of the puzzle?

Viability testing and transplantation of marginal livers (VITTAL) using normothermic machine perfusion: study protocol for an open-label, non-randomised, prospective, single-arm trial

Recent solid-phase microextraction-based analytical approaches for the profiling of biliary bile acids in pre-transplant assessments of liver grafts subjected to normothermic ex vivo liver perfusion

Combination of Early Allograft Dysfunction and Protein Expression Patterns Predicts Outcome of Liver Transplantation From Donation After Cardiac Death